2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
We'll know a little more about the company's prospects by the end of the year.
Overview
Should you invest in CRISPR Therapeutics (NASDAQ: CRSP) before the end of the year? The company's shares have slightly underperformed the broader market to date, but the biotech may see several catalysts that could send its share price jumping over the next four months. Here are two reasons why investors might want to consider loading up on CRISPR Therapeutics right now.
Unlike most of its similarly sized peers that specialize in gene editing, CRISPR Therapeutics has launched a product, Casgevy, which earned approval in 2023. Casgevy treats two rare blood diseases: transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). CRISPR Therapeutics collaborated with Vertex Pharmaceuticals (NASDAQ: VRTX) to develop it. Though the medicine was a breakthrough, it hasn't generated much sales yet. Here are two reasons why.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.